This project is funded by a BBSRC CASE PhD studentship for 4 years. The industrial partner is AstraZeneca (Cambridge).
1. Farrell B & Breeze AL (2018) Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc Trans 46, 1753-1770. doi: 10.1042/BST20180004
2. Patani H, et al. (2016) Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget Mar 16. doi: 10.18632/oncotarget.8132
2. Klein T, et al. (2015) Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nat. Commun. 6, 7877. doi: 10.1038/ncomms8877
3. Bunney T et al. (2018) Disease Variants of FGFR3 Reveal Molecular Basis for the Recognition and Additional Roles for Cdc37 in Hsp90 Chaperone System. Structure 26, 446-458. doi: 10.1016/j.str.2018.01.016
FTE Category A staff submitted: 60.90
Research output data provided by the Research Excellence Framework (REF)Click here to see the results for all UK universities